Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (August 2025)
40 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, Aug 21, 2025
Slide 1: Annual Shareholders' Meeting
Annual Shareholders' Meeting 1 21 August 2025
Slide 2: Online Help
Online Help 2 Fisher&Paykel HEALTHCARE
Slide 3: Your Board
Your Board Neville Mitchell Lewis Gradon Sir Michael Daniell Pip Greenwood Lisa McIntyre Graham McLean Mark Cross Cather Simpson 3
Slide 4: Agenda
Agenda • Chair’s Address • Managing Director and Chief Executive Officer’s Address • Financial Statements • Resolutions • Voting • General Questions 4
Slide 5: Neville Mitchell, Board Chair
Neville Mitchell Board Chair 5
Slide 6: Fisher & Paykel Healthcare
5 Fisher & Paykel HEALTHCARE
Slide 7: FY2025 financial highlights
FY2025 financial highlights Operating Revenue $2.02B 14% Underlying Net Profit After Tax $377.2M 30% Total Dividend 42.50cps 2% Constant currency growth rates for revenue and net profit after tax 7
Slide 8: Dividend
Dividend DIVIDEND HISTORY • Increased final dividend by 2% 45 compared with FY24 40 • Total dividend for the year represents a payout of 66% of 35 FY25 net profit 30 Dividend (CPS) 25 20 15 10 5 0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Interim cps Final cps Total cps 8
Slide 9: Fisher & Paykel Healthcare
3 Fisher & Paykel HEALTHCARE
Slide 10: Your Board
Your Board Neville Mitchell Lewis Gradon Sir Michael Daniell Pip Greenwood Lisa McIntyre Graham McLean Mark Cross Cather Simpson 10
Slide 11: Pip Greenwood, Retiring director
Pip Greenwood Retiring director 11
Slide 12: Neville Mitchell, Board Chair
Neville Mitchell Board Chair 12
Slide 13: Lewis Gradon, Managing Director and CEO
Lewis Gradon Managing Director and CEO 13
Slide 14: Video: A look back at FY25
Video: A look back at FY25 14 Fisher & Paykel HEALTHCARE
Slide 15: US Tariffs - Current state
YW Cc oO we D O 1 WY qe qe co (0) - Y) =)
Slide 16: US Tariffs - Response
US Tariffs - Response 16
Slide 17: Seasonal hospitalisations
Seasonal hospitalisations 17
Slide 18: Seasonal hospitalisations
Seasonal hospitalisations 18
Slide 19: FY26 full year outlook
FY26 full year outlook At 31 July 2025 exchange rates*, the company’s outlook for the full year remains unchanged: • Operating revenue in the range of approximately $2.15 billion to $2.25 billion • Net profit after tax in the range of approximately $390 million to $440 million If seasonal respirator
Slide 20: FY26 first half outlook
FY26 first half outlook At 31 July exchange rates*, guidance assumptions for the first half of the 2026 financial year include a continuation of the current trading environment and result in: • revenue of approximately $1.075 billion • net profit after tax of approximately $200 million. This would e
Slide 21: Revenue growth since 2001
Revenue growth since 2001 Revenue in NZ$ millions by financial year 2,500 22 million patients $2.02 billion 2,000 1,500 1,000 500 0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 21
Slide 22: 10-year financial performance
10-year financial performance Revenue Net profit after tax $2.0b $500m $1.5b $400m $1.0b $300m $200m $0.5b $100m $0.0b $0m 15 16 17 18 19 20 21 22 23 24 25 15 16 17 18 19 20 21 22 23 24 25 Note: FY24 net profit after tax excludes the impact of product recall, land revaluation, and removal of buildin
Slide 23: Our aspiration
Our aspiration OUR ASPIRATION: Sustainably DOUBLING our constant currency revenue every 5-6 years. The image above is an illustration of the company’s long-term growth aspirations. It is not a graph and should not be interpreted as being 23 indicative of levels of revenue or profitability in the sho
Slide 24: Lewis Gradon, Managing Director and CEO
Lewis Gradon Managing Director and CEO 24
Slide 25: Neville Mitchell, Board Chair
Neville Mitchell Board Chair 25
Slide 26: Financial statements
Financial statements • Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor’s report or the company’s 2025 annual report. • There will be an opportunity to ask any general questions once all items on the agenda have been considered. 26
Slide 27: Resolutions
Resolutions 1. Re-election of Neville Mitchell 2. Re-election of Lewis Gradon 3. Re-election of Lisa McIntyre 4. Re-election of Cather Simpson 5. Election of Mark Cross 6. Auditor’s Remuneration 7. Long Term Variable Remuneration to Lewis Gradon 27
Slide 28: How to vote online
How to vote online Voting box Question box 28
Slide 29: Lisa McIntyre, People & Remuneration Committee Chair
Lisa McIntyre People & Remuneration Committee Chair 29
Slide 30: Resolution 1: Re-election of Neville Mitchell
Resolution 1: Re-election of Neville Mitchell That Neville Mitchell, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 30
Slide 31: Resolution 2: Re-election of Lewis Gradon
Resolution 2: Re-election of Lewis Gradon That Lewis Gradon, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 31
Slide 32: Resolution 3: Re-election of Lisa McIntyre
Resolution 3: Re-election of Lisa McIntyre That Lisa McIntyre, who retires by rotation and, being eligible, offers herself for re-election, be re-elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 32
Slide 33: Resolution 4: Re-election of Cather Simpson
Resolution 4: Re-election of Cather Simpson That Cather Simpson, who retires by rotation and, being eligible, offers herself for re-election, be re-elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 33
Slide 34: Resolution 5: Election of Mark Cross
Resolution 5: Election of Mark Cross That Mark Cross, who being eligible, offers himself for election, be elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 34
Slide 35: Resolution 6: Auditor's Remuneration
Resolution 6: Auditor’s Remuneration That the Directors be authorised to fix the fees and expenses of PwC as the Company’s auditor. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 35
Slide 36: Resolution 7: Long Term Variable Remuneration
Resolution 7: Long Term Variable Remuneration That the grant of discretionary long term variable remuneration instruments to Lewis Gradon, Managing Director and Chief Executive Officer. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 36
Slide 37: Neville Mitchell, Board Chair
Neville Mitchell Board Chair 37
Slide 38: Proxy voting snapshot
Proxy voting snapshot Returned votes Resolution For % Against Abstain as a % of issued capital 1: Re-election of Neville Mitchell 426,452,705 96.9% 11,652,887 1,299,617 75.1% 2: Re-election of Lewis Gradon 438,663,775 99.5% 139,173 601,896 75.2% 3: Re-election of Lisa McIntyre 427,736,750 96.9% 11,6
Slide 39: Questions
7p) Cc Ae) rs) WY) cd) =) ©) Paykel HEALTHCARE Fisher&
Slide 40: Thank you for attending today's Annual Shareholders' Meeting
Thank you for attending today’s Annual Shareholders' Meeting 40
Fisher & Paykel Healthcare — Shareholder Meeting (August 2025) on 6ix